Skip to main navigation Skip to search Skip to main content

Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023

  • C. Henri van Werkhoven
  • , Anne Wil Valk
  • , Bente Smagge
  • , Hester E. de Melker
  • , Mirjam J. Knol
  • , Susan JM Hahné
  • , Susan van den Hof
  • , Brechje de Gier*
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Downloads (Pure)

Abstract

We present early vaccine effectiveness (VE) estimates of the 2023 seasonal COVID-19 XBB.1.5 vaccine against COVID-19 hospitalisation and admission to an intensive care unit (ICU) in previously vaccinated adults≥60 years in the Netherlands. We compared vaccination status of 2,050 hospitalisations including 92 ICU admissions with age group-, sex-, region- and date-specific population vaccination coverage between 9 October and 5 December 2023. VE against hospitalisation was 70.7% (95% CI: 66.6–74.3), VE against ICU admission was 73.3% (95% CI: 42.2–87.6).

Original languageEnglish
Article number2300703
JournalEurosurveillance
Volume29
Issue number1
DOIs
Publication statusPublished - 4 Jan 2024

Fingerprint

Dive into the research topics of 'Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023'. Together they form a unique fingerprint.

Cite this